ViroCarb Inc. is a Toronto-based biotechnology company with a paradigm-shifting drug platform that prevents viruses from replicating in cells by disrupting a host process hacked by multiple pathogenic viruses (RNA processing). Its drug candidates exhibit highly potent broad antiviral activity with excellent oral pharmacokinetic and safety profiles demonstrated in rodents. ViroCarb’s initial goal is to develop a single oral treatment for the major respiratory viral infections - COVID-19, influenza, respiratory syncytial virus (RSV) - and future emerging variants.

ViroCarb Inc.  logo



Event details

Date: June 5 - 8, 2023

Event contact

Patricia Cosgrove
Area Director
USA: Life Sciences


33 in total